ATHA · Athira Pharma, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $17.50M | $70.68M | $93.79M | $61.46M | $42.79M | $13.29M |
| SG&A | $16.68M | $26.09M | $33.30M | $32.55M | $21.23M | $6.71M |
| Total Operating Expenses | $102.27M | $100.90M | $125.47M | $104.02M | $64.02M | $20.00M |
| D&A | $972.0K | $970.0K | $969.0K | $845.0K | $479.0K | $2.0K |
| Operating Income | ($102.27M) | ($100.90M) | ($125.47M) | ($104.02M) | ($64.02M) | ($20.00M) |
| Interest Expense | - | - | - | - | $3.0K | $367.0K |
| Income Tax | $0 | - | - | - | - | - |
| Net Income | ($105.61M) | ($96.94M) | ($117.67M) | ($95.64M) | ($54.85M) | ($19.95M) |
| EPS - Basic | ($24.70) | ($2.52) | ($3.09) | ($1.49) | - | - |
| EPS - Diluted | ($24.70) | ($2.52) | ($3.09) | ($1.49) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $69.28M | $48.44M | $90.58M | $95.97M | $110.54M | $60.63M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $4.59M | $319.0K | $129.0K | $2.50M | $567.0K | $1.16M |
| Current Assets | $89.46M | $54.84M | $154.73M | $207.53M | $260.80M | $192.34M |
| Total Assets | $92.15M | $58.78M | $160.25M | $258.15M | $332.01M | $279.56M |
| Current Liabilities | $47.50M | $13.13M | $28.84M | $21.43M | $9.29M | $4.41M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $64.36M | $13.94M | $30.06M | $23.02M | $10.92M | $5.28M |
| Stockholders' Equity | $27.79M | $44.84M | $130.19M | $235.14M | $321.08M | $274.28M |
| Retained Earnings | ($511.75M) | ($406.15M) | ($309.21M) | ($191.53M) | ($95.89M) | ($41.04M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($45.73M) | ($97.17M) | ($100.75M) | ($72.47M) | ($43.10M) | ($24.11M) |
| Investing Cash Flow | ($15.89M) | $54.83M | $95.09M | $57.66M | ($4.08M) | ($210.07M) |
| Financing Cash Flow | $82.46M | $194.0K | $493.0K | $654.0K | $97.09M | $292.75M |
| CapEx | - | $33.0K | $304.0K | $1.14M | $1.57M | $2.32M |
| Free Cash Flow | - | ($97.20M) | ($101.06M) | ($73.61M) | ($44.67M) | ($26.43M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | 1.00 | 0.86 | 0.77 | 0.81 | 1.32 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -114.6% | -164.9% | -73.4% | -37.0% | -16.5% | -7.1% |
| Return on equity | -380.0% | -216.2% | -90.4% | -40.7% | -17.1% | -7.3% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.88 | 4.18 | 5.37 | 9.68 | 28.07 | 43.66 |
| Quick ratio | 1.88 | 4.18 | 5.37 | 9.68 | 28.07 | 43.66 |
| Cash ratio | 1.46 | 3.69 | 3.14 | 4.48 | 11.90 | 13.76 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | -21340.7x | -54.5x |
| Equity multiplier | 3.32 | 1.31 | 1.23 | 1.10 | 1.03 | 1.02 |
| Liabilities / Assets | 0.70 | 0.24 | 0.19 | 0.09 | 0.03 | 0.02 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -1.4% | 19.6% | -20.6% | -62.5% | -220.2% | - |
| Net income growth (YoY) | -8.9% | 17.6% | -23.0% | -74.4% | -174.9% | - |
| EPS growth (YoY) | -880.2% | 18.4% | -107.4% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | 3.8% | -37.3% | -64.8% | -69.0% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -38.0% | -65.6% | -44.6% | -26.8% | 17.1% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Athira Pharma against the 5 most active filers in the same SIC group.